MergerJul 30, 2026, 07:02 AM
Mangoceuticals to Merge with Nuclea Energy Inc.
AI Summary
Mangoceuticals, Inc. announced a definitive Business Combination Agreement with Nuclea Energy Inc., an advanced nuclear technology company. The transaction, structured with Canadian exchangeable shares, will result in Nuclea shareholders owning approximately 96% of Mangoceuticals' equity. The deal aims to bring Nuclea's Morpheus microreactor technology to public markets, capitalizing on surging power demand from AI and data centers. Leadership changes include Josef Freundorfer becoming Mangoceuticals' CEO and Jacob D. Cohen transitioning to President with a significant severance package.
Key Highlights
- Mangoceuticals entered a Business Combination Agreement with Nuclea Energy Inc. on July 29, 2026.
- Nuclea shareholders will hold approximately 96% of Mangoceuticals' equity on a fully diluted, as-exchanged basis.
- The transaction includes a minimum $15,000,000 PIPE financing.
- Josef Freundorfer will become Mangoceuticals' CEO, and Sagar Sanghera will be Executive Chairman.
- Jacob D. Cohen will transition from CEO to President, receiving $1,500,000 cash severance and 2,000,000 bonus shares.
- Cohen also receives a $10,000,000 cashless warrant for Mango & Peaches Corp. common stock.
- The aggregate economic and voting rights are limited to 19.99% of outstanding Mangoceuticals common stock until stockholder and Nasdaq approvals.
Price Impact
More from MGRX